Up-to-date prevalence at recommended ages for discontinuing routine colorectal, cervical and lung cancer screening
Menée aux Etats-Unis à partir de données portant sur 338 189 personnes éligibles au dépistage du cancer colorectal, du cancer du col de l'utérus ou du cancer du poumon, cette étude examine la prévalence actuelle du dépistage pour chacune de ces pathologies puis la prévalence de l'arrêt de ces dépistages à l'âge recommandé
Cancer screening guidelines specify ages at which routine screening should be discontinued and, except for cervical cancer screening, do not require specific screening history criteria be met for discontinuation. We estimated the prevalence of being up to date with average-risk screening guidelines for colorectal, cervical, and lung cancer as of the recommended ages for discontinuation of routine screening. We conducted a descriptive study among several U.S. healthcare systems during 2010-2019. Up-to-date screening prevalence, based on U.S. Preventive Services Task Force guidelines, was ascertained prior to 76th, 66th, and 81st birthdays among persons eligible for colorectal (N = 316,756 persons), cervical (N = 20,282 persons), and lung cancer (N = 1,151 persons) screening, respectively. Up-to-date screening prevalence was 84.4% for colorectal, 58.9% for cervical, and 6.3% for lung cancer screening. Up-to-date screening prevalence at the ages recommended for discontinuing routine colorectal, cervical, and lung cancer screening varied appreciably, and was particularly low for lung cancer screening.
Journal of the National Cancer Institute , résumé, 2026